Literature DB >> 1930777

HIV-1 infection among New York City inmates.

I B Weisfuse1, B L Greenberg, S D Back, H A Makki, P Thomas, W C Rooney, E L Rautenberg.   

Abstract

A blinded seroprevalence survey for HIV-1 infection was conducted among individuals entering New York City (NYC) prisons in 1989. Data collected included age group, race/ethnicity, syphilis serologic results and self-admitted drug use. Remnant serum specimens were tested for HIV-1 antibody by enzyme-linked immunosorbent assay and confirmed by Western blot. Of 2236 inmates surveyed, 413 (18.5%) were HIV-1 positive. Rates varied by subgroup, and were higher for women than men (25.8 versus 16.1%; odds ratio 1.8; P less than 0.01), for drug users than inmates who denied drug use (25 versus 14%; odds ratio 2.3; P less than 0.01), for intravenous heroin users (43 versus 15% in drug users not using heroin), and for inmates with positive rapid plasma reagin test (RPR) results (34.5 versus 16.1% in RPR-negative inmates). Use of intravenous heroin was most strongly related, by logistic regression, to HIV-1 seropositivity. The results are among the highest found in US inmates, and suggest that there were 12,500 seropositive individuals incarcerated in 1989. This represents approximately 10% of the estimated number of seropositive individuals in NYC. The NYC Correctional System should be viewed as a front-line institution in the fight against AIDS through provision of HIV-related prevention services and clinical care, and drug treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1930777     DOI: 10.1097/00002030-199109000-00013

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  HIV and AIDS risk behaviors among female jail detainees: implications for public health policy.

Authors:  Gary Michael McClelland; Linda A Teplin; Karen M Abram; Naomi Jacobs
Journal:  Am J Public Health       Date:  2002-05       Impact factor: 9.308

Review 2.  Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration.

Authors:  Sandro Galea; David Vlahov
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

3.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.

Authors:  Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

4.  From corrections to communities as an HIV priority.

Authors:  David Vlahov; Sara Putnam
Journal:  J Urban Health       Date:  2006-05       Impact factor: 3.671

5.  Universal radiographic screening for tuberculosis among inmates upon admission to jail.

Authors:  M C Layton; K J Henning; T A Alexander; A L Gooding; C Reid; B M Heyman; J Leung; D M Gilmore; T R Frieden
Journal:  Am J Public Health       Date:  1997-08       Impact factor: 9.308

Review 6.  The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis.

Authors:  Princess A Iroh; Helen Mayo; Ank E Nijhawan
Journal:  Am J Public Health       Date:  2015-05-14       Impact factor: 9.308

7.  Anergy compromises screening for tuberculosis in high-risk populations.

Authors:  S R Zoloth; S Safyer; J Rosen; D Michaels; P Alcabes; E Bellin; C Braslow
Journal:  Am J Public Health       Date:  1993-05       Impact factor: 9.308

8.  HIV infection in the Women's Jail, Orange County, California, 1985 through 1991.

Authors:  G A Gellert; R M Maxwell; K V Higgins; T Pendergast; N Wilker
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

9.  Prevalence of HIV infection in provincial prisons in British Columbia.

Authors:  D A Rothon; R G Mathias; M T Schechter
Journal:  CMAJ       Date:  1994-09-15       Impact factor: 8.262

10.  Predictive factors of HIV-infection in injecting drug users upon incarceration.

Authors:  V Martín; J A Caylà; M L Morís; L E Alonso; R Pérez
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.